Panthera Biopartners has secured private equity investment from Lloyds Development Capital
August 2025 — Panthera Biopartners had secured growth capital from Lloyds Development Capital Limited (LDC) to advance its geographic presence and enhance its clinical offering.
Panthera is one of the UK’s largest site management organizations (SMOs) for commercial clinical trials. Based in Preston, Lancashire, Panthera specializes in patient recruitment and the management of Phase II and Phase III clinical trials across a broad spectrum of therapeutic areas, including vaccines, cardiovascular medicine, diabetes, neurology, respiratory medicine, dermatology, rheumatology and early dementia. Its services span trial planning, data collection and patient retention. Operating six UK sites, Panthera conducts clinical trials for many of the world’s largest pharmaceutical companies and clinical research organizations (CROs).
LDC is a mid-market UK private equity firm. With LDC’s support, Panthera will seek to further expand its operations across the UK and Europe, increase the number of clinical sites, invest in technology and scale its trial delivery capabilities. As SMOs play an increasingly pivotal role in the drug development value chain, the business is well-positioned to capitalize on significant growth opportunities.
“We’re incredibly proud of what the team at Panthera has achieved and are excited to partner with LDC for this next phase of growth. Their investment will help us accelerate expansion, enhance our capabilities and continue delivering for our clients and patients. With LDC’s support and experience, we look forward to broadening our reach into Europe and expanding access to clinical trials across new regions,” said Stuart Young, CEO of Panthera.
Our role in the transaction
Oaklins S&W, based in the UK, acted as the management advisor to Panthera in securing private equity investment from LDC to support its ambitious growth strategy.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn moreCapvis has sold hessnatur to Wourth Group
Hess Natur-Textilien GmbH & Co. KG has become part of the international Wourth Group. With the change of ownership from Capvis to Wourth Group, hessnatur is entering its next phase of development. The transaction reflects the company’s successful strategic and business development in recent years, and creates a strong foundation for the future.
Learn more